Background: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (-) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach.

Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials

Berchialla P.
Co-first
;
2019-01-01

Abstract

Background: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (-) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach.
2019
11
11
1
17
https://www.mdpi.com/2072-6694/11/11/1661/pdf
Abemaciclib; Aromatase inhibitors; Fulvestrant; Metastatic breast cancer; Palbociclib; Ribociclib
Rossi V.; Berchialla P.; Giannarelli D.; Nistico C.; Ferretti G.; Gasparro S.; Russillo M.; Catania G.; Vigna L.; Mancusi R.L.; Bria E.; Montemurro F.; Cognetti F.; Fabi A.
File in questo prodotto:
File Dimensione Formato  
Rossi et al 2019 - Network Meta-analysis CDk4 - Cancers.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.42 MB
Formato Adobe PDF
1.42 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1715740
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 38
social impact